<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312661</url>
  </required_header>
  <id_info>
    <org_study_id>30102012</org_study_id>
    <nct_id>NCT02312661</nct_id>
  </id_info>
  <brief_title>Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer</brief_title>
  <acronym>OVMET</acronym>
  <official_title>Phase Ib Study of Metformin in Combination With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecularly targeted agents which inhibit the mammalian target of rapamycin (mTOR) pathway&#xD;
      and/or circumvent p53 in the induction of apoptosis are exciting potential targets in ovarian&#xD;
      cancer. Metformin is a biguanide, widely used in the treatment of type 2 diabetes mellitus,&#xD;
      that has shown anti-cancer activity in preclinical studies. The main mechanism of metformin's&#xD;
      effect is mTOR pathway inhibition and, in addition, it has been shown to circumvent&#xD;
      p53-induced apoptosis making it an exciting, potentially effective drug in ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase Ib, single-centre, dose-escalation trial with a traditional escalation rule with&#xD;
      fixed dose levels (&quot;3 + 3&quot; rule). The recommended phase II dose will be defined as the&#xD;
      maximum predefined dose level at which 0 of 3 or ≤ 1 of 6 subjects experience a drug-related&#xD;
      dose limiting toxicity (DLT) during cycle 1 and 2 of treatment. An estimated 10-20 patients&#xD;
      will be required for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a measure of safety and tolerability</measure>
    <time_frame>1-2 years</time_frame>
    <description>Data will be used to determine recommended phase 2 dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC, Tmax,Cmax) of carboplatin and paclitaxel chemotherapie</measure>
    <time_frame>1-2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin / paclitaxel /metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three-weekly cycles of carboplatin/paclitaxel chemotherapy in combination with metformin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy</description>
    <arm_group_label>Carboplatin / paclitaxel /metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles</description>
    <arm_group_label>Carboplatin / paclitaxel /metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles</description>
    <arm_group_label>Carboplatin / paclitaxel /metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced stage (FIGO III-IV), histologically confirmed and documented&#xD;
             epithelial ovarian carcinoma&#xD;
&#xD;
          -  Patients eligible for neo-adjuvant carboplatin/paclitaxel chemotherapy prior to&#xD;
             surgical debulking OR patients with relapsed or progressive ovarian cancer after&#xD;
             initial treatment eligible for palliative carboplatin/paclitaxel chemotherapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0-2&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Laboratory Requirements - within 7 days prior to enrolment:&#xD;
&#xD;
          -  absolute neutrophil count (ANC) ≥1.5 x 109/L&#xD;
&#xD;
          -  platelets &gt; 100 x 109/L&#xD;
&#xD;
          -  hemoglobin &gt;9g/dl. Patients may be transfused or use erythropoietin to maintain&#xD;
             hemoglobin values ≥ 9 g/dl.&#xD;
&#xD;
          -  hepatic function: bilirubin ≤1.5×upper limit of normal (ULN), aspartate&#xD;
             aminotransferase (AST)/ALT≤2.5×ULN&#xD;
&#xD;
          -  estimated creatinine clearance ≥ 60ml/min&#xD;
&#xD;
          -  Before patient registration/randomization, written informed consent for the trial must&#xD;
             be given according to International Conference on Harmonisation (ICH)/ good clinical&#xD;
             practice (GCP), and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or recent (within 30 days of first study dosing) treatment with another&#xD;
             investigational drug or participation in another investigational study.&#xD;
&#xD;
          -  Metformin within 4 weeks prior to enrolment.&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) metastasis&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy ≥ Common toxicity criteria (CTC) grade 2.&#xD;
&#xD;
          -  Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior&#xD;
             to study treatment start, or within 14 days with a confirmatory urine pregnancy test&#xD;
             within 7 days prior to study treatment start.&#xD;
&#xD;
          -  Women of childbearing potential (defined as &lt;2 years after last menstruation and not&#xD;
             surgically sterile) not using effective, non-hormonal means of contraception&#xD;
             (intrauterine contraceptive device, barrier method of contraception in conjunction&#xD;
             with spermicidal jelly) during the study and for 6 months after the last study&#xD;
             medication.&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs or excipients.&#xD;
&#xD;
          -  Serious active infection requiring i.v. antibiotics at enrolment.&#xD;
&#xD;
          -  Unstable medical conditions.&#xD;
&#xD;
          -  Evidence of any other medical conditions, physical examination or laboratory findings&#xD;
             that may interfere with the planned treatment, affect patient compliance or place the&#xD;
             patient at high risk from treatment related complications.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Mecdical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>November 28, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Dr. M. Jalving</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>metformin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

